NBI-5788 Neurocrine.
Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. By April 2005, enrollment for phase II trials was complete, with results expected early in 2006.